DK2018388T3 - Bisadenosinforbindelser som adenosin A2A-receptoragonister - Google Patents

Bisadenosinforbindelser som adenosin A2A-receptoragonister

Info

Publication number: DK2018388T3
Authority: DK; Denmark
Prior art keywords: bisadenosine; adenosine; compounds; receptor agonists; agonists
Prior art date: 2006-04-21

Application number

DK07724376.4T

Other languages

English (en)

Inventor

Robin Alec Fairhurst

Roger John Taylor

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-04-21

Filing date

2007-04-19

Publication date

2011-06-27

2007-04-19 Application filed by Novartis Ag filed Critical Novartis Ag

2011-06-27 Application granted granted Critical

2011-06-27 Publication of DK2018388T3 publication Critical patent/DK2018388T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Pulmonology (AREA)
Biotechnology (AREA)
Genetics & Genomics (AREA)
Epidemiology (AREA)
Pain & Pain Management (AREA)
Dermatology (AREA)
Immunology (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

DK07724376.4T 2006-04-21 2007-04-19 Bisadenosinforbindelser som adenosin A2A-receptoragonister DK2018388T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0607950.3A GB0607950D0 (en)	2006-04-21	2006-04-21	Organic compounds
PCT/EP2007/003439 WO2007121924A2 (en)	2006-04-21	2007-04-19	Bisadenosine compounds as adenosine a2a receptor agonists

Publications (1)

Publication Number	Publication Date
DK2018388T3 true DK2018388T3 (da)	2011-06-27

Family

ID=36581047

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK07724376.4T DK2018388T3 (da)	2006-04-21	2007-04-19	Bisadenosinforbindelser som adenosin A2A-receptoragonister

Country Status (32)

Country	Link
US (1)	US8193164B2 (da)
EP (1)	EP2018388B9 (da)
JP (1)	JP2009534341A (da)
KR (1)	KR20080112399A (da)
CN (1)	CN101437829B (da)
AR (1)	AR060606A1 (da)
AT (1)	ATE502040T1 (da)
AU (1)	AU2007241347A1 (da)
CA (1)	CA2648037A1 (da)
CL (1)	CL2007001132A1 (da)
CR (1)	CR10328A (da)
CY (1)	CY1111568T1 (da)
DE (1)	DE602007013203D1 (da)
DK (1)	DK2018388T3 (da)
EC (1)	ECSP088837A (da)
ES (1)	ES2363255T3 (da)
GB (1)	GB0607950D0 (da)
GT (1)	GT200800218A (da)
HR (1)	HRP20110445T1 (da)
IL (1)	IL194398A0 (da)
MA (1)	MA30404B1 (da)
MX (1)	MX2008013398A (da)
NO (1)	NO20084456L (da)
PE (1)	PE20071228A1 (da)
PL (1)	PL2018388T3 (da)
PT (1)	PT2018388E (da)
RU (1)	RU2008145715A (da)
SI (1)	SI2018388T1 (da)
TN (1)	TNSN08409A1 (da)
TW (1)	TW200813074A (da)
WO (1)	WO2007121924A2 (da)
ZA (1)	ZA200808103B (da)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GT200500281A (es)	2004-10-22	2006-04-24	Novartis Ag	Compuestos organicos.
EP1831225A2 (en)	2004-11-19	2007-09-12	The Regents of the University of California	Anti-inflammatory pyrazolopyrimidines
GB0500785D0 (en)	2005-01-14	2005-02-23	Novartis Ag	Organic compounds
EA200870409A1 (ru)	2006-04-04	2009-04-28	Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния	Антагонисты киназы pi3
GB0607950D0 (en)	2006-04-21	2006-05-31	Novartis Ag	Organic compounds
RU2457209C2 (ru)	2006-04-21	2012-07-27	Новартис Аг	Производные пурина, предназначенные для применения в качестве агонистов аденозинового рецептора а2а
GB0607944D0 (en) *	2006-04-21	2006-05-31	Novartis Ag	Organic compounds
EP1889846A1 (en)	2006-07-13	2008-02-20	Novartis AG	Purine derivatives as A2a agonists
EP1903044A1 (en)	2006-09-14	2008-03-26	Novartis AG	Adenosine Derivatives as A2A Receptor Agonists
CN101553459A (zh) *	2006-11-10	2009-10-07	诺瓦提斯公司	环戊烯二醇单乙酸酯衍生物
GB2467670B (en)	2007-10-04	2012-08-01	Intellikine Inc	Chemical entities and therapeutic uses thereof
US20090181934A1 (en) *	2007-10-17	2009-07-16	Novartis Ag	Organic Compounds
WO2009050199A1 (en) *	2007-10-17	2009-04-23	Novartis Ag	Purine derivatives as adenosine al receptor ligands
US8193182B2 (en)	2008-01-04	2012-06-05	Intellikine, Inc.	Substituted isoquinolin-1(2H)-ones, and methods of use thereof
MX2010007419A (es)	2008-01-04	2010-11-12	Intellikine Inc	Ciertas entidades quimicas, composiciones y metodos.
EP2252293B1 (en)	2008-03-14	2018-06-27	Intellikine, LLC	Kinase inhibitors and methods of use
WO2009114874A2 (en)	2008-03-14	2009-09-17	Intellikine, Inc.	Benzothiazole kinase inhibitors and methods of use
EP3009436B1 (en)	2008-07-08	2019-06-05	Intellikine, LLC	Kinase inhibitors and methods of use
US20110224223A1 (en)	2008-07-08	2011-09-15	The Regents Of The University Of California, A California Corporation	MTOR Modulators and Uses Thereof
JP5731978B2 (ja)	2008-09-26	2015-06-10	インテリカイン，エルエルシー	複素環キナーゼ阻害剤
AU2009305669A1 (en)	2008-10-16	2010-04-22	The Regents Of The University Of California	Fused ring heteroaryl kinase inhibitors
US8476282B2 (en)	2008-11-03	2013-07-02	Intellikine Llc	Benzoxazole kinase inhibitors and methods of use
WO2010129816A2 (en)	2009-05-07	2010-11-11	Intellikine, Inc.	Heterocyclic compounds and uses thereof
US8980899B2 (en)	2009-10-16	2015-03-17	The Regents Of The University Of California	Methods of inhibiting Ire1
CN103002738A (zh)	2010-05-21	2013-03-27	英特利凯恩有限责任公司	用于激酶调节的化学化合物、组合物和方法
AU2011326427B2 (en)	2010-11-10	2016-01-07	Infinity Pharmaceuticals Inc.	Heterocyclic compounds and uses thereof
UA115767C2 (uk)	2011-01-10	2017-12-26	Інфініті Фармасьютікалз, Інк.	Способи отримання ізохінолінонів і тверді форми ізохінолінонів
EP2678018A4 (en)	2011-02-23	2015-09-30	Intellikine Llc	COMBINATION OF CHINESE HEMMER AND USES THEREOF
US8969363B2 (en)	2011-07-19	2015-03-03	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
WO2013012918A1 (en)	2011-07-19	2013-01-24	Infinity Pharmaceuticals Inc.	Heterocyclic compounds and uses thereof
AU2012302197B2 (en)	2011-08-29	2016-01-07	Infinity Pharmaceuticals Inc.	Heterocyclic compounds and uses thereof
CA2846496C (en)	2011-09-02	2020-07-14	The Regents Of The University Of California	Substituted pyrazolo[3,4-d]pyrimidines and uses thereof
US8940742B2 (en)	2012-04-10	2015-01-27	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
US8828998B2 (en)	2012-06-25	2014-09-09	Infinity Pharmaceuticals, Inc.	Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
RU2015115631A (ru)	2012-09-26	2016-11-20	Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния	Модулирование ire1
US9481667B2 (en)	2013-03-15	2016-11-01	Infinity Pharmaceuticals, Inc.	Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
MX2021012208A (es)	2013-10-04	2023-01-19	Infinity Pharmaceuticals Inc	Compuestos heterocíclicos y usos de los mismos.
US9751888B2 (en)	2013-10-04	2017-09-05	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
CN113616656B (zh)	2014-03-19	2023-02-17	无限药品股份有限公司	用于治疗PI3K-γ介导的障碍的杂环化合物
US20150320755A1 (en)	2014-04-16	2015-11-12	Infinity Pharmaceuticals, Inc.	Combination therapies
US9708348B2 (en)	2014-10-03	2017-07-18	Infinity Pharmaceuticals, Inc.	Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
WO2017048702A1 (en)	2015-09-14	2017-03-23	Infinity Pharmaceuticals, Inc.	Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
US10759806B2 (en)	2016-03-17	2020-09-01	Infinity Pharmaceuticals, Inc.	Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
US10919914B2 (en)	2016-06-08	2021-02-16	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
US11147818B2 (en)	2016-06-24	2021-10-19	Infinity Pharmaceuticals, Inc.	Combination therapies
US20200055883A1 (en)	2017-02-17	2020-02-20	Eisai R&D Management Co., Ltd.	Cyclic di-nucleotides derivative for the treatment of cancer

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1528382A (en)	1974-12-26	1978-10-11	Teijin Ltd	Cyclopentene diols and acyl esters thereof and processes for their preparation
US4738954A (en)	1985-11-06	1988-04-19	Warner-Lambert Company	Novel N6 -substituted-5'-oxidized adenosine analogs
US4873360A (en)	1986-07-10	1989-10-10	Board Of Governors Of Wayne State University	Process for the preparation of cyclopentanoids and novel intermediates produced thereby
US4954504A (en)	1986-11-14	1990-09-04	Ciba-Geigy Corporation	N9 -cyclopentyl-substituted adenine derivatives having adenosine-2 receptor stimulating activity
EP0267878A1 (en)	1986-11-14	1988-05-18	Ciba-Geigy Ag	N9-cyclopentyl-substituted adenine derivatives
JP2586897B2 (ja)	1987-03-09	1997-03-05	富士薬品工業株式会社	光学活性なシス−シクロペンテン−３，５−ジオ−ルモノエステルの製造法
ATE147074T1 (de)	1990-09-25	1997-01-15	Rhone Poulenc Rorer Int	Verbindungen welche antihypertensive und antiischemische eigenschaften besitzen
IT1254915B (it)	1992-04-24	1995-10-11	Gloria Cristalli	Derivati di adenosina ad attivita' a2 agonista
US5688774A (en)	1993-07-13	1997-11-18	The United States Of America As Represented By The Department Of Health And Human Services	A3 adenosine receptor agonists
US5691188A (en)	1994-02-14	1997-11-25	American Cyanamid Company	Transformed yeast cells expressing heterologous G-protein coupled receptor
ATE219767T1 (de)	1996-01-02	2002-07-15	Aventis Pharm Prod Inc	Verfahren zur herstellung von 2,4-dihydroxy- pyridin und 2,4-dihydroxy-3-nitropyridin
US6376472B1 (en)	1996-07-08	2002-04-23	Aventis Pharmaceuticals, Inc.	Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties
EP0991414A4 (en)	1997-05-09	2002-10-02	Univ Pennsylvania	METHODS FOR REDUCING CARDIAC ISCHEMIC LESION BY ADMINISTRATION OF ADENOSINE RECEPTOR AGONISTS AND ANTAGONISTS AND RELATED COMPOSITIONS
GB9813554D0 (en)	1998-06-23	1998-08-19	Glaxo Group Ltd	Chemical compounds
EP1090022B1 (en)	1998-06-23	2003-08-06	Glaxo Group Limited	2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
GB9813540D0 (en)	1998-06-23	1998-08-19	Glaxo Group Ltd	Chemical compounds
GB9813535D0 (en)	1998-06-23	1998-08-19	Glaxo Group Ltd	Chemical compounds
AU5879299A (en)	1998-10-16	2000-05-08	Monaghan, Sandra Marina	Adenine derivatives
BR9917000A (pt)	1998-12-31	2001-12-11	Aventis Pharm Prod Inc	Processo para preparar derivados dedesaza-adenosina n6-substituìda
US7427606B2 (en)	1999-02-01	2008-09-23	University Of Virginia Patent Foundation	Method to reduce inflammatory response in transplanted tissue
US6322771B1 (en)	1999-06-18	2001-11-27	University Of Virginia Patent Foundation	Induction of pharmacological stress with adenosine receptor agonists
US6403567B1 (en)	1999-06-22	2002-06-11	Cv Therapeutics, Inc.	N-pyrazole A2A adenosine receptor agonists
US6214807B1 (en)	1999-06-22	2001-04-10	Cv Therapeutics, Inc.	C-pyrazole 2A A receptor agonists
US6586413B2 (en)	1999-11-05	2003-07-01	The United States Of America As Represented By The Department Of Health And Human Services	Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists
GB0003960D0 (en)	2000-02-18	2000-04-12	Pfizer Ltd	Purine derivatives
GB0022695D0 (en)	2000-09-15	2000-11-01	Pfizer Ltd	Purine Derivatives
JP4012070B2 (ja)	2001-01-16	2007-11-21	カン−フィテ・バイオファーマ・リミテッド	ウイルスの複製を阻害するためのアデノシンａ３受容体アゴニストの使用
GB2372741A (en)	2001-03-03	2002-09-04	Univ Leiden	C2,8-Disubstituted adenosine derivatives and their different uses
US20040162422A1 (en)	2001-03-20	2004-08-19	Adrian Hall	Chemical compounds
EP1258247A1 (en)	2001-05-14	2002-11-20	Aventis Pharma Deutschland GmbH	Adenosine analogues for the treatment of insulin resistance syndrome and diabetes
AU2002362443B2 (en)	2001-10-01	2008-05-15	University Of Virginia Patent Foundation	2-propynyl adenosine analogs having A2A agonist activity and compositions thereof
US7414036B2 (en)	2002-01-25	2008-08-19	Muscagen Limited	Compounds useful as A3 adenosine receptor agonists
WO2003086408A1 (en)	2002-04-10	2003-10-23	University Of Virginia Patent Foundation	Use of a2a adenosine receptor agonists for the treatment of inflammatory diseases
PL1699459T3 (pl)	2003-12-29	2007-12-31	Can Fite Biopharma Ltd	Sposób leczenia stwardnienia rozsianego
BRPI0508488A (pt)	2004-03-05	2007-07-31	Cambridge Biotechnology Ltd	compostos terapêuticos
EP1746885A4 (en)	2004-05-03	2010-09-08	Univ Virginia	ADENOSINE A2A RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETIC NEPHROPATHY
PE20060272A1 (es)	2004-05-24	2006-05-22	Glaxo Group Ltd	(2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
EP1781604B1 (en) *	2004-06-23	2013-08-07	Synta Pharmaceuticals Corp.	Bis(thio-hydrazide amide) salts for treatment of cancers
US7825102B2 (en)	2004-07-28	2010-11-02	Can-Fite Biopharma Ltd.	Treatment of dry eye conditions
PL1778239T3 (pl)	2004-07-28	2014-01-31	Can Fite Biopharma Ltd	Agoniści receptora adenozynowego A3 do leczenia zaburzeń suchego oka w tym zespołu Sjogrena
EP1794162A1 (en)	2004-09-09	2007-06-13	The Government of the United States of America, as repres. by the Secretary of Health and Human Services, Nat. Inst. of Health	Purine derivatives as a3 and a1 adenosine receptor agonists
GT200500281A (es)	2004-10-22	2006-04-24	Novartis Ag	Compuestos organicos.
US20080051364A1 (en)	2004-11-08	2008-02-28	Pninna Fishman	Therapeutic Treatment of Accelerated Bone Resorption
GB0500785D0 (en)	2005-01-14	2005-02-23	Novartis Ag	Organic compounds
US7951810B2 (en)	2005-02-04	2011-05-31	Millennium Pharmaceuticals, Inc.	Substituted pyrrolo[2,3-d]pyrimidines as inhibitors of E1 activating enzymes
GB0505219D0 (en)	2005-03-14	2005-04-20	Novartis Ag	Organic compounds
GB0514809D0 (en)	2005-07-19	2005-08-24	Glaxo Group Ltd	Compounds
CA2622879C (en)	2005-11-30	2011-07-05	Can-Fite Biopharma Ltd.	Use of a3 adenosine receptor agonist in osteoarthritis treatment
DK1983990T3 (da)	2006-01-26	2011-07-11	Us Gov Health & Human Serv	Allosteriske A3-adenosin-receptormodulatorer
PL1989206T3 (pl)	2006-02-02	2012-11-30	Millennium Pharm Inc	Inhibitory enzymu aktywującego E1
US20080027022A1 (en)	2006-02-08	2008-01-31	Linden Joel M	Method to treat gastric lesions
GB0607948D0 (en)	2006-04-21	2006-05-31	Novartis Ag	Organic compounds
GB0607953D0 (en)	2006-04-21	2006-05-31	Novartis Ag	Organic compounds
GB0607945D0 (en)	2006-04-21	2006-05-31	Novartis Ag	Organic compounds
RU2457209C2 (ru)	2006-04-21	2012-07-27	Новартис Аг	Производные пурина, предназначенные для применения в качестве агонистов аденозинового рецептора а2а
GB0607950D0 (en)	2006-04-21	2006-05-31	Novartis Ag	Organic compounds
GB0607944D0 (en)	2006-04-21	2006-05-31	Novartis Ag	Organic compounds
GB0607954D0 (en)	2006-04-21	2006-05-31	Novartis Ag	Organic compounds
GB0607951D0 (en)	2006-04-21	2006-05-31	Novartis Ag	Organic compounds
EP1889846A1 (en)	2006-07-13	2008-02-20	Novartis AG	Purine derivatives as A2a agonists
US8008307B2 (en)	2006-08-08	2011-08-30	Millennium Pharmaceuticals, Inc.	Heteroaryl compounds useful as inhibitors of E1 activating enzymes
EP1903044A1 (en)	2006-09-14	2008-03-26	Novartis AG	Adenosine Derivatives as A2A Receptor Agonists
CN101553459A (zh)	2006-11-10	2009-10-07	诺瓦提斯公司	环戊烯二醇单乙酸酯衍生物
US20080312160A1 (en)	2007-04-09	2008-12-18	Guerrant Richard L	Method of treating enteritis, intestinal damage, and diarrhea from c. difficile with an a2a adenosine receptor agonist
US20080262001A1 (en)	2007-04-23	2008-10-23	Adenosine Therapeutics, Llc	Agonists of a2a adenosine receptors for treating recurrent tumor growth in the liver following resection
AU2008270735C1 (en)	2007-06-29	2014-03-06	Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services	Dendrimer conjugates of agonists and antagonists of the GPCR superfamily
WO2009050199A1 (en)	2007-10-17	2009-04-23	Novartis Ag	Purine derivatives as adenosine al receptor ligands
US20090181934A1 (en)	2007-10-17	2009-07-16	Novartis Ag	Organic Compounds
US8183225B2 (en)	2007-11-08	2012-05-22	New York University	Inhibition of bone resorption using medical implants containing adenosine receptor antagonists
WO2009089425A1 (en)	2008-01-09	2009-07-16	Pgxhealth Llc	Intrathecal treatment of neuropathic pain with a2ar agonists

2006
- 2006-04-21 GB GBGB0607950.3A patent/GB0607950D0/en not_active Ceased
2007
- 2007-04-19 PT PT07724376T patent/PT2018388E/pt unknown
- 2007-04-19 AR ARP070101685A patent/AR060606A1/es not_active Application Discontinuation
- 2007-04-19 DK DK07724376.4T patent/DK2018388T3/da active
- 2007-04-19 CN CN2007800144171A patent/CN101437829B/zh not_active Expired - Fee Related
- 2007-04-19 PL PL07724376T patent/PL2018388T3/pl unknown
- 2007-04-19 SI SI200730609T patent/SI2018388T1/sl unknown
- 2007-04-19 JP JP2009505783A patent/JP2009534341A/ja not_active Withdrawn
- 2007-04-19 AU AU2007241347A patent/AU2007241347A1/en not_active Abandoned
- 2007-04-19 CA CA002648037A patent/CA2648037A1/en not_active Abandoned
- 2007-04-19 RU RU2008145715/04A patent/RU2008145715A/ru not_active Application Discontinuation
- 2007-04-19 DE DE602007013203T patent/DE602007013203D1/de active Active
- 2007-04-19 PE PE2007000481A patent/PE20071228A1/es not_active Application Discontinuation
- 2007-04-19 EP EP07724376A patent/EP2018388B9/en active Active
- 2007-04-19 WO PCT/EP2007/003439 patent/WO2007121924A2/en active Application Filing
- 2007-04-19 ES ES07724376T patent/ES2363255T3/es active Active
- 2007-04-19 MX MX2008013398A patent/MX2008013398A/es not_active Application Discontinuation
- 2007-04-19 AT AT07724376T patent/ATE502040T1/de active
- 2007-04-19 US US12/297,491 patent/US8193164B2/en not_active Expired - Fee Related
- 2007-04-19 KR KR1020087028409A patent/KR20080112399A/ko not_active Application Discontinuation
- 2007-04-20 TW TW096114111A patent/TW200813074A/zh unknown
- 2007-04-20 CL CL200701132A patent/CL2007001132A1/es unknown
2008
- 2008-09-22 ZA ZA200808103A patent/ZA200808103B/xx unknown
- 2008-09-25 IL IL194398A patent/IL194398A0/en unknown
- 2008-09-30 CR CR10328A patent/CR10328A/es not_active Application Discontinuation
- 2008-10-17 GT GT200800218A patent/GT200800218A/es unknown
- 2008-10-17 TN TNP2008000409A patent/TNSN08409A1/en unknown
- 2008-10-21 EC EC2008008837A patent/ECSP088837A/es unknown
- 2008-10-22 NO NO20084456A patent/NO20084456L/no not_active Application Discontinuation
- 2008-11-10 MA MA31368A patent/MA30404B1/fr unknown
2011
- 2011-06-14 HR HR20110445T patent/HRP20110445T1/hr unknown
- 2011-06-16 CY CY20111100573T patent/CY1111568T1/el unknown

Also Published As

Publication number	Publication date
AU2007241347A1 (en)	2007-11-01
GT200800218A (es)	2008-12-15
MA30404B1 (fr)	2009-05-04
ES2363255T3 (es)	2011-07-28
TNSN08409A1 (en)	2010-04-14
GB0607950D0 (en)	2006-05-31
TW200813074A (en)	2008-03-16
CA2648037A1 (en)	2007-11-01
CN101437829A (zh)	2009-05-20
IL194398A0 (en)	2009-08-03
EP2018388B1 (en)	2011-03-16
US20100190784A1 (en)	2010-07-29
AR060606A1 (es)	2008-07-02
CR10328A (es)	2008-11-18
CY1111568T1 (el)	2015-10-07
ECSP088837A (es)	2008-11-27
PL2018388T3 (pl)	2011-08-31
EP2018388A2 (en)	2009-01-28
ATE502040T1 (de)	2011-04-15
JP2009534341A (ja)	2009-09-24
KR20080112399A (ko)	2008-12-24
RU2008145715A (ru)	2010-05-27
PT2018388E (pt)	2011-06-27
PE20071228A1 (es)	2008-01-24
EP2018388B9 (en)	2011-10-05
CN101437829B (zh)	2012-03-21
SI2018388T1 (sl)	2011-07-29
WO2007121924A2 (en)	2007-11-01
HRP20110445T1 (hr)	2011-07-31
DE602007013203D1 (de)	2011-04-28
CL2007001132A1 (es)	2008-05-23
NO20084456L (no)	2008-12-09
MX2008013398A (es)	2008-11-04
WO2007121924A3 (en)	2008-09-04
US8193164B2 (en)	2012-06-05
ZA200808103B (en)	2009-07-29

Publication	Publication Date	Title
DK2018388T3 (da)	2011-06-27	Bisadenosinforbindelser som adenosin A2A-receptoragonister
DK2066669T3 (da)	2011-01-10	Adenosinderivater som A2A-receptoragonister
DK2013211T3 (da)	2012-07-02	Purinderivater til anvendelse som adenosin-A2A-receptoragonister
DK1841768T3 (da)	2009-03-02	Purinderivater virkende som A2A-receptoragonister
CY2020044I1 (el)	2021-03-12	1΄-υποκατεστημενα αναλογα καρβα-νουκλεοζιδιων για αντιιικη αγωγη
DK1989196T3 (da)	2013-04-15	Piperidinoylpyrrolidiner som melanocortin-type 4-receptoragonister
ATE549350T1 (de)	2012-03-15	Neuropeptid-2-rezeptor-agonisten
DK2206710T3 (da)	2012-08-27	Indolderivater som s1p1-receptor agonister
BRPI0817503A2 (pt)	2015-05-05	Derivados de purina substituídos por pirimidina
DK1863474T3 (da)	2009-02-09	Hidtil ukendte thiophenderivater som sphingosin-1-phosphat-1-receptoragonister
BRPI0819797A2 (pt)	2019-09-24	compostos de nucleosídeos antivirais
DK2114980T3 (da)	2012-09-24	Antivirale nukleosidanaloger
DK2069322T3 (da)	2012-11-05	THIOPHENDERIVATER SOM S1P1/EDG1-receptoragonister
CR10520A (es)	2009-03-19	Derivados de purina como agonistas de a2a
IL201234A0 (en)	2010-05-31	Adenosine a2a receptor antagonists
ATE502016T1 (de)	2011-04-15	Triazolo-ä1,5-aü-chinoline als adenosin-a3- rezeptorliganden
DE502007004416D1 (de)	2010-08-26	Avermectinderivate
ZA200702635B (en)	2008-07-30	Purine derivatives for use as adenosin A-2A receptor agonists
DK2276756T3 (da)	2012-03-26	Hydroxymethylpyrrolidiner som beta 3-adrenerge receptoragonister
IL177721A0 (en)	2006-12-31	Adenosine receptor agonists